Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan

Nakazawa T., Takahashi K., Kuwayama Y., Nomura A., Shimada F.

2022
Advances in Therapy

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Department of Ophthalmology, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan; Department of Ophthalmology, Kansai Medical University, 2-5-1 Shin-machi, Osaka, Hirakata, 573-1010, Japan; Fukushima Eye Clinic, 5-6-16, Fukushima, Fukushima-ku, Osaka, 553-0003, Japan; Santen Pharmaceutical Co., Ltd, 4-20, Ofukacho, Kita-ku, Osaka, 530-8552, Japan

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group

Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.

Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.

View all Glaucoma publications